Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Regenxbio (RGNX) over the last 11 years, with Q3 2025 value amounting to $34.4 million.

  • Regenxbio's Current Deferred Revenue rose 2378888.89% to $34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year increase of 2378888.89%. This contributed to the annual value of $115000.0 for FY2024, which is 2229.73% down from last year.
  • Regenxbio's Current Deferred Revenue amounted to $34.4 million in Q3 2025, which was up 2378888.89% from $37.8 million recorded in Q2 2025.
  • Regenxbio's 5-year Current Deferred Revenue high stood at $39.9 million for Q1 2025, and its period low was $13000.0 during Q1 2024.
  • Moreover, its 5-year median value for Current Deferred Revenue was $3.3 million (2021), whereas its average is $7.8 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 9900.84% in 2024, then skyrocketed by 30682307.69% in 2025.
  • Regenxbio's Current Deferred Revenue (Quarter) stood at $3.3 million in 2021, then plummeted by 45.12% to $1.8 million in 2022, then crashed by 91.91% to $148000.0 in 2023, then dropped by 22.3% to $115000.0 in 2024, then soared by 29813.04% to $34.4 million in 2025.
  • Its last three reported values are $34.4 million in Q3 2025, $37.8 million for Q2 2025, and $39.9 million during Q1 2025.